back to Meetings page
Participants
Agenda
Background Materials
  • IMMPACT-XIX Slide Presentations

  • 1. Precision pain medicine: accomplishments of the past 25 years, and prospects for the next 10
  • Clifford Woolf, MD, PhD
  • 2. Preclinical research obstacles and opportunities in developing precision pain medicine: an overview
  • Andrew Rice, MBBS, MD
  • 3. Clinical research obstacles and opportunities in developing precision pain medicine: an overview
  • Michael Rowbotham, MD
  • 4. Precision medicine at the NIH
  • William Riley, PhD
  •  
  • 5. Rare vs. common gene variants as guides to pain mechanisms and drug development
  • Alban Latremoliere, PhD
  • 6. Sodium channels as targets for precision pain medicine: preclinical perspectives
  • Simon Tate, PhD
  • 7. Sodium channels as targets for precision pain medicine: "irritable nociceptors" and other phenotypes
  • in the design of clinical trials
  • Troels Jensen, MD, PhD
  • 8. COX inhibitors and NGF antibodies as targets for precision pain medicine
  • Nathaniel Katz, MD
  • 9. Descending inhibition as a target for precision pain medicine
  • Roland Staud, MD
  • 10. Signs, symptoms, and comprehensive QST: a perspective from the German Research Network on Neuropathic Pain
  • Ralf Baron, MD
  •  
  • 11. Signs, symptoms, and bedside QST: α2-δ and other targets
  • Roy Freeman, MD
  • 12. Non-pharmacologic treatments in precision pain medicine: rationale for splitting (stratifying) vs. lumping
  • Dennis Turk, PhD
  • 13. What else needs to be included when phenotyping is considered?
  • Robert Edwards, PhD